Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Heart Failure With Preserved Ejection Fr...
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Heart failure with preserved ejection fraction (HFpEF) is a condition in which the heart cannot fill with blood effectively. As a result, people with HFpEF suffer fatigue, breathlessness, and develop swollen limbs. The condition often requires multiple admissions to hospital and is associated with a marked loss of lifespan. Despite being so common, very little is known about why people develop HFpEF and there are hardly any known treatments. Type 2 diabetes (T2D) is a major risk factor for HFpEF, and people with both HFpEF and diabetes are at a heightened risk of hospitalisation and premature death. It is unclear why the combination of diabetes and HFpEF is particularly harmful. This may be related to the hearts of people with type 2 diabetes being unable to take up the mineral calcium properly, as well as due to their hearts being less energy efficient. Both of these are vital to heart muscle pumping and filling, but until recently it has not been possible to assess these in humans. New advances in heart MRI scans, with dedicated scanner techniques and dyes (manganese contrast), now allow extremely detailed pictures of heart structure, function, calcium uptake and energy efficiency, all during the same scan. The investigators will enlist 40 volunteers with HFpEF (20 with T2D and 20 without T2D), and up to 20 healthy volunteers, to undergo a heart MRI scan with manganese contrast to assess calcium uptake and energy efficiency. This will allow the comparison of people with HFpEF with and without T2D, to see how their hearts are different to healthy volunteers.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Minnesota Living with Heart Failure Questionnaire — Self-administered, validated questionnaire to assess symptoms of heart failure
  • Diagnostic Test: Echocardiogram — Resting transthoracic echocardiogram to exclude valvular pathology and the assess indices of systolic and diastolic function and speckle tracking for strain
  • Diagnostic Test: Six-minute walk test — Standardised, objective assessment of exercise capacity
  • Diagnostic Test: Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy — Using a 3-Tesla scanner, 31P magnetic resonance spectroscopy will be performed to obtain information regarding cardiac energetics. An intravenous infusion of manganese dipyridoxyl diphosphate (mangafodipir, MnDPDP) will be commenced at a rate of 1mL/min using a dose of 5µmol/kg (0.1mL/kg).
  • Diagnostic Test: Cardiovascular magnetic resonance scan — Scan including adenosine stress perfusion
  • Diagnostic Test: Blood tests — Full blood count, Urea and electrolytes, Liver function tests, Glucose and HbA1c, Insulin and C-peptide, NTproBNP, High sensitive troponin I, storage of plasma for future analyses

Primary Outcomes

  • Ki (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-10
Completion: 2036-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Leicester
Principal Investigators:
  • Gerry P McCann, MD (PRINCIPAL_INVESTIGATOR) - University of Leicester
  • Abhishek Dattani, MBBS (PRINCIPAL_INVESTIGATOR) - University of Leicester
Contact Information
Study Contact:
Gerry P McCann, MD
+44 (0)116 258 3038
gpm12@leicester.ac.uk
Abhishek Dattani, MBBS
ad530@leicester.ac.uk
Gerry P McCann, MD
0116 2583038
gpm12@leicester.ac.uk
University of Leicester
Interventions
  • Other: Minnesota Living with Heart Failure Questionnaire — Self-administered, validated questionnaire to assess symptoms of heart failure
  • Diagnostic Test: Echocardiogram — Resting transthoracic echocardiogram to exclude valvular pathology and the assess indices of systolic and diastolic function and speckle tracking for strain
  • Diagnostic Test: Six-minute walk test — Standardised, objective assessment of exercise capacity
  • Diagnostic Test: Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy — Using a 3-Tesla scanner, 31P magnetic resonance spectroscopy will be performed to obtain information regarding cardiac energetics. An intravenous infusion of manganese dipyridoxyl diphosphate (mangafodipir, MnDPDP) will be commenced at a rate of 1mL/min using a dose of 5µmol/kg (0.1mL/kg).
  • Diagnostic Test: Cardiovascular magnetic resonance scan — Scan including adenosine stress perfusion
Study Locations (1 sites)
University of Leicester, Leicester, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Capacity to provide informed consent * Symptoms (e.g. breathlessness, orthopnoea, ankle swelling, fatigue), signs (e.g. elevated jugular venous pressure, peripheral oedema, third heart sound) or established diagnosis of HF with LV ejection fraction ≥ 50%, or * Meets HFpEF diagnostic criteria in accordance with the HFA-PEFF diagnostic algorithm form the Heart Failure Association of the European Society of Cardiology, in which a score ≥5 points confirms diagnosis of HFpEF Exclusion Criteria: * Known diagnosis of Type 1 Diabetes * Pregnancy or breast-feeding or females of child bearing age without a negative pregnancy test * Receiving an investigational drug or device within 30 days prior to participating in the study * Decompensated heart failure or pulmonary oedema * History of prolonged corrected QT interval or torsades de pointes * Second- or third-degree atrioventricular block * Abnormal liver function tests (\> 3x upper limit of normal) or history of liver disease * Baseline eGFR \< 30mL/min/1.73m2 * Any contraindications to MRI including implanted devices/pacemakers * Severe native valve disease, restrictive cardiomyopathy, constrictive pericarditis or hypertrophic cardiomyopathy, myocarditis or takotsubo cardiomyopathy. * Recent myocardial infarction within the previous 3 months * Known diagnosis of pheochromocytoma
Conditions Type 2 Diabetes, Overweight and Obesity
Phase NA
Enrollment 150
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this two-site grant proposal is to determine the role of the decreased insulin-mediated muscle perfusion found in type 2 diabetes in contributing to the development of cardiac and skeletal muscle dysfunction and subsequent functional exercise impairment. In addition, it is also our goal to determine whether exercise training attenuates insulin resistance and restores insulin-mediated perfusion to the heart and to skeletal muscle, leading to improved cardiac function and exercise performance.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cardiovascular exercise — 15 weeks of cardiovascular exercise 3x/week for 50 minutes/session

Primary Outcomes

  • Change in peak oxygen consumption (VO2) (Through study completion, approximately 4 months)
  • Change in insulin sensitivity (Through study completion, approximately 4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-06-17
Completion: 2027-02-15
Eligibility
Age: 30 Years – 55 Years
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Collaborators: University of Virginia, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact Information
Study Contact:
Benjamin Juckett, MS
303-724-1338
benjamin.juckett@cuanschutz.edu
Benjamin Juckett, MS
303-724-1338
benjamin.juckett@cuanschutz.edu
University of Colorado
Ethan Clark, MS
303-724-1354
ethan.w.clark@cuanschutz.edu
University of Colorado
Interventions
  • Behavioral: Cardiovascular exercise — 15 weeks of cardiovascular exercise 3x/week for 50 minutes/session
Study Locations (2 sites)
University of Colorado, Aurora, Colorado 80045 United States
University of Virginia, Charlottesville, Virginia 22908 United States
Eligibility Criteria
Inclusion Criteria: * Sedentary (defined as less than 1 hour per week of physical activity) * BMI: 25-40 * Men and women with and without type 2 diabetes Exclusion Criteria: * Documented cardiovascular disease * Uncontrolled hypertension: disease systolic blood pressure (SBP) \> 150, diastolic blood pressure (DBP)\> 110 * Obstructive pulmonary disease or asthma * Peripheral neuropathy * Physical impairment that would limit exercise ability * Subjects taking beta blockers, calcium channel blockers, insulin, or Thiazolidinediones (TZD) * Current or past smoking within the last 1 years * Current tobacco use * Anemia * Control HbA1c \> 5.7, T2DM HbA1c \> 9 * Pregnant, nursing or hormonal therapy (other than contraceptives) * Peri or post-menopausal women * Type 1 diabetes * Hepatic or renal disease.
Conditions Asthma
Phase NA
Enrollment 400
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This study is an efficacy-implementation trial to: 1. evaluate systematically the efficacy of BREATHE in 200 Black adults receiving care at urban federally qualified health centers (FQHCs) for uncontrolled asthma; and 2. identify multi-level barriers and facilitators to the widespread adoption and implementation of BREATHE in FQHCs.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: BREATHE Intervention — BREATHE utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
  • Behavioral: Control Intervention — The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).

Primary Outcomes

  • Mean Asthma Control Questionnaire Score (Baseline, 1 month, 2 months, 3 months, 6 months, 9 months, 12 Months (post-intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-01-19
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Columbia University
Collaborators: National Institute of Nursing Research (NINR)
Principal Investigators:
  • Maureen George, PhD (PRINCIPAL_INVESTIGATOR) - Columbia University School of Nursing
Contact Information
Study Contact:
Maureen George, PhD
2123051175
mg3656@cumc.columbia.edu
Maureen George, PhD
212-305-1175
mg3656@cumc.columbia.edu
Sun River Health
Maureen George, PhD
212-305-1175
mg3656@cumc.columbia.edu
Bedford Stuyvesant Family Health Center
Interventions
  • Behavioral: BREATHE Intervention — BREATHE utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
  • Behavioral: Control Intervention — The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
Study Locations (2 sites)
Sun River Health, Beacon, New York 12508 United States
Bedford Stuyvesant Family Health Center, Brooklyn, New York 11216 United States
Eligibility Criteria
Inclusion Criteria (participants): Patients participants will 1. be adults (\> or = 18 years of age) 2. self-report race as 'Black' race (African American, African, Caribbean, West Indian, multi-racial \[Black AND one or more additional races\]); identify their ethnicity as Hispanic OR non-Hispanic 3. have clinician-diagnosed persistent asthma (defined as being prescribed inhaled corticosteroids in the last 48 months) or have had an asthma exacerbation (e.g., ER visit, course of Prednisone) regardless of controller medicine use 4. receive asthma care at a partner FQHC and 5. screen positive for uncontrolled asthma as measured by the Asthma Control Questionnaire- 6 items (ACQ-6) and erroneous beliefs as measured by the Conventional and Alternative Management for Asthma (CAM-A) survey. Exclusion Criteria (participants): 1. non-English speaking 2. serious mental health conditions that preclude completion of study procedures or confound analyses or 3. participation in a listening session Inclusion Criterion (clinicians): 1\. those who manage a panel of adult asthma patients Inclusion Criteria (loved ones): 1. must be identified by patient participant as a loved one and 2. loved one must be a family member or friend of the patient participant. Exclusion Criteria (loved ones): 1. non-English speaking or 2. serious mental health conditions that preclude completion of study procedures or confound analyses
Conditions Severe Asthma, Asthma
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Physical activity has been shown to improve asthma control in individuals with asthma. Patients with severe asthma frequently experience exacerbations, which often result in a physically inactive lifestyle. The investigators therefore hypothesize that patients with severe asthma who initiate biological therapy may particularly benefit from increased physical activity, both in terms of exercise capacity and asthma control. The aim of this study is to determine whether an individually tailored exercise program improves exercise capacity and asthma control in patients with severe asthma. Additionally, the study evaluates the effects of the intervention on asthma symptoms, frequency of exacerbations, lung function, quality of life, and body composition. The primary outcome is the change in exercise tolerance, measured as peak oxygen uptake during cardiopulmonary exercise testing. Secondary outcomes include asthma symptoms (proportion of patients reporting improvement based on the Asthma Control Test), frequency of exacerbations, changes in lung function (FVC and FEV1), asthma-related quality of life (AQLQ), and changes in body composition (body mass index and waist circumference). At baseline, all participants undergo fitness assessments, including cardiopulmonary exercise testing and muscle strength tests. Participants are then randomized into two groups. The intervention group receives an individually tailored 6-month exercise program designed by a sports medicine physician and a physiotherapist based on baseline fitness level. The control group receives standard advice to increase physical activity. Asthma medication is managed according to standard clinical practice in both groups. Fitness assessments are repeated at 6 months for all participants, and asthma control is evaluated at 6 and 12 months

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Exercise intervention — a 6 month personilized exercise plan with control and follow up including baseline fitness testing

Primary Outcomes

  • The change in peak O2 consumption (from enrollment to the end of the follow up period (6 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-18
Completion: 2028-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Helsinki University Central Hospital
Principal Investigators:
  • Mika Mäkelä, prof (STUDY_CHAIR) - Helsinki University Central Hospital
Contact Information
Study Contact:
Hanna Hisinger-Mölkänen, MD, PhD
+358 40 6654484
hanna.hisinger-molkanen@hus.fi
Annina Lyly, MD, PhD
+358 50 4287952
annina.lyly@hus.fi
Hanna Hisinger-Mölkänen, MD, PhD
+358 40 6654484
hanna.hisinger-molkanen@hus.fi
Helsinki University Hospital
Interventions
  • Other: Exercise intervention — a 6 month personilized exercise plan with control and follow up including baseline fitness testing
Study Locations (1 sites)
Helsinki University Hospital, Helsinki, 00250 Finland
Eligibility Criteria
Inclusion Criteria: * Age over 18 years * Physician-diagnosed severe asthma defined with the GINA criteria and with a decision to initiate biological treatment (omalizumab, mepolizumab, benralizumab, dupilumab or tezepelumab) for severe asthma Exclusion Criteria: * Upcoming major surgery * Acute musculoskeletal disease which unables regular exercise * Inability to commit to the appointments and the exercise plan due to exhaustion or fatigue * Pregnancy
Conditions Asthma
Phase PHASE2
Enrollment 42
Locations 23 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo. Outcome of this study will be used to determine the dose of inhaled glycopyrronium for the development of fixed dose combination indacaterol/mometasone/glycopyrronium (QVM149) for children aged 6 to less than 12 years old with moderate to severe asthma.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Glycopyrronium bromide 25ug — 25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler
  • Drug: Placebo — Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
  • Drug: Glycopyrronium bromide 12.5ug — 12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Primary Outcomes

  • Change from Baseline in trough FEV1 (At the start and end of each 2 week treatment period (Days 1, 14, 29, 42, 57 and 70))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-08-29
Completion: 2027-08-30
Eligibility
Age: 6 Years – 11 Years
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com
Novartis Pharmaceuticals
Interventions
  • Drug: Glycopyrronium bromide 25ug — 25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler
  • Drug: Placebo — Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
  • Drug: Glycopyrronium bromide 12.5ug — 12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler
Study Locations (23 sites)
Novartis Investigative Site, Rousse, 7002 Bulgaria
Novartis Investigative Site, Sevlievo, 5400 Bulgaria
Novartis Investigative Site, Sofia, 1510 Bulgaria
Novartis Investigative Site, Ibague, Tolima Department 730006 Colombia
Novartis Investigative Site, Guatemala City, GTM 01010 Guatemala
Novartis Investigative Site, Guatemala City, 01015 Guatemala
Novartis Investigative Site, Debrecen, Hajdu Bihar Megye 4032 Hungary
Novartis Investigative Site, Budapest, 1033 Hungary
Novartis Investigative Site, Budapest, 1083 Hungary
Novartis Investigative Site, Eger, 3300 Hungary
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of asthma for at least 6 months * Signed informed consent by parent(s)/legal guardian(s) and assent by the pediatric participant (depending on local requirements) * Participant on stable dose of inhaled low-to-medium dose ICS with one additional controller for at least 4 weeks prior to run-in * Pre-Bronchodilator FEV1 ≥60% to ≤90% of predicted normal at beginning of Run-in and randomization. If FEV1 eligibility criteria are not met at -45min pre-dose of the End of Run-in (Visit 30), the visit can be rescheduled once within 5 days from the previous attempt. * FEV1 reversibility, done using up to 4 puffs of SABA (up to 400μg salbutamol or 360μg albuterol) at Run-in visit (Visit 20): increase \> and/or = 12% (performed according to American Thoracic Society (ATS)/European Respiratory Society (ERS) 2019 guidelines). All participants must perform a reversibility test at start of Run-in. If reversibility is not demonstrated at Run-in, it may be attempted at up to two ad hoc, unscheduled separate visits within 5 days from previous attempt. If reversibility is still not demonstrated after repeated assessment participants must be screen failed * Demonstrated acceptable inhaler use technique for Diskus/Accuhaler (prior to run-in) and Breezhaler (prior to randomization) and able to complete spirometry procedures prior to randomization. * A parent/legal guardian must be designated to complete all e-Diary entries and attend all clinic visits with the participant. * Parents/legal guardian must be willing and able to assist the child with the procedures outlined in the protocol, e.g. compliance with study medication, completion of electronic participant diary * Female participants of child-bearing potential, who might become sexually active, must be informed of the need to prevent pregnancy during the study using effective contraceptive methods. The decision on the contraceptive method should be reviewed at least every 3 months to evaluate the individual need and compatibility of the method chosen. Exclusion Criteria: * Systemic corticosteroid use for any reason within 3 months of Run-in * Participants on low to medium mono ICS alone * Participants requiring six or more puffs of rescue medication per day on more than two consecutive days in the four weeks prior to Screening (Visit 1) and/or in the four weeks prior to the Run-in visit * Participants who have had an asthma attack/exacerbation requiring a) systemic corticosteroids (SCS) or b) hospitalization or c) emergency room visit, within 3 months prior to Screening (Visit 1), or more than 3 separate exacerbations in the 12 months preceding the Screening visit * Participants with a known narrow-angle glaucoma, bladder dysfunction, bladder outlet obstruction or any other conditions where anticholinergic treatment is contraindicated prior to Screening (Visit 1) * Participants with a history of long QT syndrome or whose corrected QT interval (QTc) measured at start of Run-in and confirmed at Baseline (prior to randomization) (Fridericia method) is prolonged (\> 450 msec for boys and girls) and confirmed by a central assessor (these patients should not be rescreened) * Suspected or documented active infections (bacterial, viral, fungal, mycobacterial or other, including active SARS-CoV-2, tuberculosis or atypical mycobacterial disease) of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 6 weeks of Screening (Visit 1) * History of Type I diabetes or uncontrolled Type II diabetes * Participants who are sexually active at screening * Hemoglobin levels outside normal ranges at Run-in (Visit 20) * Female patients of childbearing potential (e.g., are menstruating) who do not agree to abstinence or, if they become sexually active during study participation, do not agree to the use of contraception as defined in the inclusion criteria. Additional protocol-defined inclusion / exclusion criteria may apply.
Conditions Asthma Acute, Asthma Childhood, Asthma i...
Phase Not Applicable
Enrollment 500
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Standardization According to GINA 2025 Recommendations for the Treatment, Management, and Follow-up of Acute Asthma Attacks: Observational, Multicenter Cohort Study.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in the number of correctly reported diagnoses before and after intervention (Pre-intervention and through study completion, an average of 9 months)
  • Percentage of patients with correct timing, dosage, and method of drug administration before and after intervention (Pre-intervention and through study completion, an average of 9 months)
  • Percentage of patients with correct follow-up at discharge (Pre-intervention and through study completion, an average of 9 months)
  • Percentage of patients in whom additional drugs are used in refractory cases (Pre-intervention and through study completion, an average of 9 months)
  • Percentage of patients with correct therapy at discharge (Pre-intervention and through study completion, an average of 9 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-05
Completion: 2026-06-30
Eligibility
Age: 6 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Meyer Children's Hospital IRCCS
Contact Information
Study Contact:
Grazia Fenu
+390555662388
grazia.fenu@meyer.it
Luca Di Napoli, MD
Arcispedale S. Anna
Interventions
N/A
Study Locations (2 sites)
Arcispedale S. Anna, Ferrara, FE 44124 Italy
Meyer Children's Hospital IRCCS, Firenze, Florence, 50134 Italy
Eligibility Criteria
Inclusion Criteria: * Age between 6 and 17 years * Presentation to the emergency department with a diagnosis of acute asthma exacerbation * Evaluation in the emergency department of one of the participating centers during the study periods Exclusion Criteria: * Age \< 6 years or \> 17 years * Diagnosis other than acute asthma exacerbation * Incomplete or missing clinical data * Patients transferred from other hospitals already treated for the same episode * history of allergy to any drugs used in the protocol
Conditions Asthma in Children, Intellectual Disabil...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Correct use of daily medications containing inhaled corticosteroids is key for asthma control, yet children with intellectual and developmental disabilities (IDD) face additional barriers to proper inhaler use. Smart inhalers, a novel technology that provides guidance and immediate feedback on inhaler use techniques, have been shown to enhance correct medication administration in the typically developing pediatric population, but their effectiveness has not been evaluated on the pediatric IDD population. This study aims to investigate whether daily application of smart inhalers (1) is feasible and acceptable in the IDD population, (2) improves the rate of correct medication administration, and (3) results in improvement in lung function. This effort aims to promote better asthma management in the IDD population.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Use of smart inhaler to enhance asthma inhaler proficiency — The application of the smart inhaler technology to enhance asthma inhaler proficiency

Primary Outcomes

  • Feasibility of smart inhaler device (Weeks 1-8)
  • Acceptability of smart inhaler (Weeks 4 and 8)
  • Usability of smart inhaler (Weeks 4 and 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-13
Completion: 2025-04
Eligibility
Age: 10 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital Los Angeles
Principal Investigators:
  • Larry Yin, MD, MSPH (PRINCIPAL_INVESTIGATOR) - Children's Hospital Los Angeles
Contact Information
Study Contact:
Sophia Park, MD
323-669-2534
soppark@chla.usc.edu
Alexis Deavenport-Saman, DrPH, MPH
323-361-2994
adeavenport@chla.usc.edu
Sophia Park, MD
323-669-2534
soppark@chla.usc.edu
Children's Hospital Los Angeles
Interventions
  • Behavioral: Use of smart inhaler to enhance asthma inhaler proficiency — The application of the smart inhaler technology to enhance asthma inhaler proficiency
Study Locations (1 sites)
Children's Hospital Los Angeles, Los Angeles, California 90027 United States
Eligibility Criteria
Inclusion Criteria: Participants must meet all of the inclusion criteria to participate in this study: * Adolescents ages 10-17 years * Diagnosis of mild-to-moderate intellectual disability: ICD-10: F70-F71 and/or diagnosis of developmental disability, including autism: ICD-10: F80-89 * Diagnosis of moderate-to-severe asthma or moderate or severe unspecified asthma: ICD-10: J45.40-J45.909 * Parent/legal guardian is willing to answer questions about their child. * Parent/legal guardian and adolescent must have the ability to understand study procedures and to comply with them for the entire length of the study * English or Spanish-speaking participants * Not involved in other studies using digital inhalers * Males and females of reproductive capability will be enrolled: contraception is not necessary or required. * Participants must use any of the following MDIs (as indicated by the 510(k): Ventolin HFA, ProAir HFA, Advair HFA, Flovent HFA, Xopenex HFA, Symbicort HFA, Atrovent HFA, Proventil HFA, Alvesco HFA, Dulera HFA, and Asmanex HFA. Exclusion Criteria: All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation: * Health status or any clinical conditions: Limited life expectancy, co-existing disease or other characteristics that precludes appropriate diagnosis, treatment, or follow-up in the trial. * Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
Conditions Asthma in Children
Phase PHASE2
Enrollment 105
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Randomized controlled trial of soluble fiber (Fruitafit Inulin). Participants will complete an ASA 24 dietary recall questionnaire to access their fiber intake. If eligible for the study, participants will be supplemented to their target fiber dosage with either soluble fiber (Fruitafit Inulin) or placebo. Collection of blood serum, fecal samples, and nasal wash will aid in analyzing the microbes present in one's gut and how fiber and diet may impact it. Thus, allowing researchers to better understand the pathways that may connect diet and asthma and if it is possible to improve asthma by altering one's diet.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Inulin — Soluble tapioca starch from Ingredion.

Primary Outcomes

  • Alpha diversity. (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-11-10
Completion: 2027-05-31
Eligibility
Age: 6 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 105 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Phoenix Children's Hospital
Collaborators: Northern Arizona University, National Institute on Minority Health and Health Disparities (NIMHD), Southwest Health Engagement and Research Collaborative, SHERC
Principal Investigators:
  • Matthew Rank (PRINCIPAL_INVESTIGATOR) - Phoenix Children's
Contact Information
Study Contact:
Daniel Gastaldo
6029334979
dgastaldo@phoenixchildrens.com
Matthew Rank
Rank.Matthew@mayo.edu
Daniel Gastaldo
602-933-4979
dgastaldo@phoenixchildrens.com
Phoenix Children's
Interventions
  • Drug: Inulin — Soluble tapioca starch from Ingredion.
Study Locations (1 sites)
Phoenix Children's, Phoenix, Arizona 85016 United States
Eligibility Criteria
Inclusion Criteria: * Between ages 6-17 * Asthma diagnosis within the last 2 years * Fractional excretion of exhaled nitric oxide (FeNO) \> 50 ppb OR a clinical history of environmental allergies as defined by a positive skin prick or positive specific immunoglobulin E (IgE) tests to aeroallergens * No emergency department visits in the past 1 month * Ability to consume a liquid drink of fiber or placebo * Ability to return for a 4-6 week follow-up visit * No special or unique diet Exclusion Criteria: * Cystic fibrosis * Bronchiectasis * Change in asthma medicines other than short acting bronchodilators planned over the next 4-6 weeks * Baseline estimated daily fiber intake less than or equal to 16 grams as determined by the ASA 24 * Sibling of a participant already enrolled in the study
Conditions Asthma
Phase NA
Enrollment 28
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized controlled clinical trial is to evaluate the effects of a proposed educational intervention on people with asthma. The main question it aims to contribute to a better understanding of the effectiveness of educational intervention strategies in people with asthma. Participants allocated to the control group will receive standard follow-up according to the clinic routine. Participants allocated to the experimental group will undergo an educational intervention BUNDLE, prepared in accordance with the recommendations of the Global Initiative for Asthma- GINA (2024).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Other: Educational intervention BUNDLE, prepared in accordance with the recommendations of the Global Initiative for Asthma- GINA (2024)). — The educational intervention bundle was designed in accordance with the recommendations of GINA (2024), and will cover topics on the etiopathogenesis and pathophysiology of asthma, inhaler treatment, precipitating factors for crises, self-management skills, environmental control, as well as the importance of drawing up a written therapeutic plan and regular medical follow-up. The educational intervention will be offered as a group activity and will be conducted in a single meeting, lasting approximately sixty minutes. Users will attend a standardized dialogical lecture using audiovisual resources, where they will have the opportunity to discuss and answer any questions related to the topics covered. At the end of the intervention, participants will receive a booklet containing all the points covered in the intervention, as well as a diary to record the amount of medication used, visits to the emergency room and asthma-related hospitalizations.

Primary Outcomes

  • clinical asthma control (Baseline and 4 weeks)
  • Retention of information about asthma knowledge and inhalation therapy (Baseline and 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03
Completion: 2025-10
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: false
Enrollment: 28 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Federal University of Paraíba
Contact Information
Study Contact:
Renata Tomaz, PhD
5583999351535
renatatomazf@gmail.com
Pulmonary Function Clinic of the Department of Physiotherapy at Federal University of Paraiba
Interventions
  • Other: Educational intervention BUNDLE, prepared in accordance with the recommendations of the Global Initiative for Asthma- GINA (2024)). — The educational intervention bundle was designed in accordance with the recommendations of GINA (2024), and will cover topics on the etiopathogenesis and pathophysiology of asthma, inhaler treatment, precipitating factors for crises, self-management skills, environmental control, as well as the importance of drawing up a written therapeutic plan and regular medical follow-up. The educational intervention will be offered as a group activity and will be conducted in a single meeting, lasting approximately sixty minutes. Users will attend a standardized dialogical lecture using audiovisual resources, where they will have the opportunity to discuss and answer any questions related to the topics covered. At the end of the intervention, participants will receive a booklet containing all the points covered in the intervention, as well as a diary to record the amount of medication used, visits to the emergency room and asthma-related hospitalizations.
Study Locations (1 sites)
Pulmonary Function Clinic of the Department of Physiotherapy at Federal University of Paraiba, João Pessoa, Paraíba 58051-900 Brazil
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of asthma * Assisted by the Pulmonary Function Clinic * Ventilatory dysfunction assessed by spirometry Exclusion Criteria: * Obesity * Treatment with systemic corticosteroids * Previous chest surgery * Unable to perform any of the proposed assessment steps
Conditions Asthma
Phase PHASE4
Enrollment 182
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to compare the efficacy of a one-time IM dose of dexamethasone versus a 5-day course of prednisone in adult ED patients presenting with asthma exacerbations. This is a randomized, controlled, double-blind, non-inferiority trial conducted at two urban EDs within the Montefiore Health System.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Dexamethasone 16mg IM — Dexamethasone 16mg Intramuscular Administration Once
  • Drug: Prednisone 60mg PO — Prednisone 60mg PO for 5 Days

Primary Outcomes

  • Asthma Control Test Score (Within 4 Weeks post-discharge, up to 28-30 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-07-23
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 182 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Montefiore Medical Center
Principal Investigators:
  • Carlo Lutz, MD (PRINCIPAL_INVESTIGATOR) - Montefiore Medical Center
Contact Information
Study Contact:
Mustfa Manzur, MD MPH MS
718-920-6626
mmanzur@montefiore.org
Mustfa Manzur, MD MPH MS
718-920-6626
mmanzur@montefiore.org
Montefiore Medical Center
Interventions
  • Drug: Dexamethasone 16mg IM — Dexamethasone 16mg Intramuscular Administration Once
  • Drug: Prednisone 60mg PO — Prednisone 60mg PO for 5 Days
Study Locations (1 sites)
Montefiore Medical Center, The Bronx, New York 10467 United States
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years old presenting to the ED with an asthma exacerbation * Diagnosed with asthma per International Classification of Diseases, 10th Revision (ICD-10) criteria or by the treating clinician * Discharged from the ED with a primary diagnosis of asthma exacerbation * Initiated systemic corticosteroids during the ED visit * Must be English or Spanish speaking Exclusion Criteria: * Current use of systemic corticosteroids, including Emergency Medical Services (EMS) administration before ED arrival * History of severe adverse reactions to corticosteroids * Heart failure and uncontrolled diabetes (glucose \>300mg/dL in the ED) * Pregnancy or breastfeeding as prednisone is the preferred treatment for asthma in this population * Inability to provide informed consent
Conditions Anxiety, Depression, Depression, Anxiety...
Phase NA
Enrollment 96
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this research study is to adapt an ACT-self-help workbook to the prison setting and determine the feasibility acceptability, and effectiveness of this workbook. Participants can expect to be in the study for 13 weeks.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Acceptance and Commitment Therapy (ACT) — ACT: Therapy that builds in traditional cognitive behavioral therapy principles but emphasizes different processes in behavior change. Delivered over 8 weeks of self-guided study and homework assignments.
  • Behavioral: Reflective Journaling — As control condition, reflective journaling will be used.

Primary Outcomes

  • Eligible participants (Study duration, up to 1 year)
  • Participants who choose to participate (Study duration, up to 1 year)
  • Percentage of participants that complete all 8 weeks (Study duration, up to 1 year)
  • Qualitative Summary of Reasons for Attrition (Study duration, up to 1 year)
  • Number of Participants referred for Follow up care (Up to 13 weeks)
  • Participant Satisfaction (Up to 13 weeks)
  • Change in Mental Health: Flexibility (Baseline to 13 weeks)
  • Change in Mental Health: Automatic Thoughts (Baseline to 13 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-09
Completion: 2026-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 96 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Wisconsin, Madison
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Michael Koenigs, PhD (PRINCIPAL_INVESTIGATOR) - University of Wisconsin, Madison
Contact Information
Study Contact:
Madilyn Michels
920-602-5612
mgmichels@wisc.edu
Interventions
  • Behavioral: Acceptance and Commitment Therapy (ACT) — ACT: Therapy that builds in traditional cognitive behavioral therapy principles but emphasizes different processes in behavior change. Delivered over 8 weeks of self-guided study and homework assignments.
  • Behavioral: Reflective Journaling — As control condition, reflective journaling will be used.
Study Locations (1 sites)
University of Wisconsin, Madison, Wisconsin 53705 United States
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Reading level of 6th grade or higher determined by the Wide Range Achievement Test * Moderate or severe anxiety and/or depression determined by the Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI) * No active self-harm or active suicidal intent * No scheduled transfer or release for at least three months * Must be willing and able to participate, including having permission and ability to use study materials, such as paper and a writing utensil Exclusion Criteria: * Unable to provide informed consent * Active self-harm or suicidal intent * Scheduled transfer or release within three months
Conditions Stroke, Post-stroke Depression
Phase NA
Enrollment 76
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Cardiac rehabilitation is the standard-of-care treatment option for patients with cardiovascular disease and has been shown to improve many aspects critical to patient recovery. Investigators believe that individuals who have had a stroke need to be treated similarly. Investigators will study the effects of a comprehensive modified cardiac rehabilitation program to determine if it can improve some of the physical and psychosocial problems common in survivors of stroke with and without depression.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Physical capacity training for chronic stroke - building aerobic capacity and muscle strength — The general format of each exercise session includes assessment of resting heart rate (HR), blood pressure (BP), and rating of perceived exertion (RPE) followed by a 5-minute warm-up, a minimum of 30 minutes of aerobic exercise followed by 25 minutes of resistance exercise. Aerobic exercise will always include a minimum of 10 minutes of walking (overground or treadmill) at the prescribed intensity followed by cycle, arm or rowing ergometry. Sessions will begin at a target intensity of \~60% heart rate reserve (HRR) determined from the exercise tolerance test performed at baseline and calculated using Karvonen's formula. The goal will be to increase training intensity by \~5% HRR every \~3 weeks and progressed as tolerated. Resistance exercise will target all major muscle groups and include multiple sets dosed at the 10-repetition to fatigue level (\~75% of the 1-repetition maximum). Resistance exercises will be progressed with improvements in strength or as tolerated.

Primary Outcomes

  • Six-minute walk test (From enrollment to the end of treatment at 12 weeks)
  • Stroke Impact Scale (From enrollment to the end of treatment at 12 weeks)
  • Hamilton Depression Rating Scale - 17 (From enrollment to the end of treatment at 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-05
Completion: 2029-08
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 76 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigators:
  • Ryan Ross (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Ryan E Ross, Ph.D.
843-792-3477
rossre@musc.edu
Ryan E Ross, Ph.D.
843-792-3477
rossre@musc.edu
Medical University of South Carolina
Ryan E Ross, Ph.D.
Medical University of South Carolina
Interventions
  • Behavioral: Physical capacity training for chronic stroke - building aerobic capacity and muscle strength — The general format of each exercise session includes assessment of resting heart rate (HR), blood pressure (BP), and rating of perceived exertion (RPE) followed by a 5-minute warm-up, a minimum of 30 minutes of aerobic exercise followed by 25 minutes of resistance exercise. Aerobic exercise will always include a minimum of 10 minutes of walking (overground or treadmill) at the prescribed intensity followed by cycle, arm or rowing ergometry. Sessions will begin at a target intensity of \~60% heart rate reserve (HRR) determined from the exercise tolerance test performed at baseline and calculated using Karvonen's formula. The goal will be to increase training intensity by \~5% HRR every \~3 weeks and progressed as tolerated. Resistance exercise will target all major muscle groups and include multiple sets dosed at the 10-repetition to fatigue level (\~75% of the 1-repetition maximum). Resistance exercises will be progressed with improvements in strength or as tolerated.
Study Locations (1 sites)
Medical University of South Carolina, Charleston, South Carolina 29425 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-80 * A diagnosis of stroke at least 6 months prior * Residual paresis in the lower extremity (Fugl-Meyer lower extremity \[LE\] motor score \<34) * Ability to walk without assistance and without an AFO during testing and training at speeds ranging from 0.2-1.0 m/s * Ability to follow instructions, complete cognitive testing and to communicate exertion, pain and distress * No antidepressant medications or no change in doses of psychotropic medication for at least 4 weeks prior to the study (6 weeks if newly initiated medication) * HDRS17 question #3 and PHQ-9 question #9 regarding suicide ≤ 2 * Provision of informed consent. In addition, depressed subjects will screen for probable major depressive disorder (Patient Health Questionnaire-9 ≥ 10) and be diagnosed using the Structured Clinical Interview for Depression (SCID) according to the DSM-5. Exclusion Criteria: * Unable to ambulate at least 150 feet or experienced intermittent claudication while walking * Unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during ADL's * Dementia * Life expectancy \<1 yr * History of DVT or pulmonary embolism within 6 months * Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions * Severe hypertension with systolic \>200 mmHg and diastolic \>110 mmHg at rest * Attempt of suicide in the last 2 years or suicidal risk assessed by depression screening * Current enrollment in a rehabilitation trial to enhance motor, cognitive and or psychosocial recovery * Severe cognitive impairment (MoCA score ≤15) * Moderate to severe neglect that precludes cognitive testing For brain stimulation procedures only: * Electronic or metallic implants * History of seizures * Women of child bearing potential